GlaxoSmithKline, in collaboration with Samsung Biologics expands production of biological medicines

GlaxoSmithKline and Samsung Biologics signed an agreement that will allow GSK to increase production of biological drugs, PharmaTimes reports.

The parties agreed that Samsung Biologics will provide GSK with additional production capacity and its amount will depend on the current needs of GSK. Transaction value of more than 231 million dollars lies for 8 years.

Initially, GSK plans to produce at the facilities of Samsung Biologics belimumab, technology transfer will start this year and the beginning of commercial production of the drug is scheduled for 2022.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]